XTSXEBM
Market cap23mUSD
Jan 08, Last price
0.50CAD
1D
-1.00%
1Q
-48.44%
IPO
-80.20%
Name
Eastwood Bio-Medical Canada Inc
Chart & Performance
P/E
—
P/S
39.29
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
3.13%
Revenues
868k
-33.22%
Net income
-547k
L+240.38%
CFO
-17k
L+293.29%
Earnings
Jul 11, 2025
Profile
Eastwood Bio-Medical Canada Inc. markets and distributes natural health products under the Eleotin brand in Canada, the United States, and Asia. It distributes Eleotin that provide natural remedies for metabolic disorders, such as blood glucose disorders, hypertension, and obesity. The company's licensed products include Eleotin A 700 for the treatment for spleen deficiency, lack of appetite, and fatigue; Eleotin AL88 for laxative; Eleotin Cal20 for bone and teeth maintenance; Eleotin V3D for development and maintenance of bones, teeth, and good health; Eleotin G2000 for cardiovascular health; Eleotin H55 for sedative and tension relief; and Eleotin Zn330 for tissue formation and metabolism. Its products also include Eleotin Bentley to promote healthy glucose levels; and Eleotin LBM for hypertension relief. The company was incorporated in 2010 and is based in Richmond, Canada.
Valuation
Title CAD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑10 | 2022‑10 | 2021‑10 | 2020‑10 | 2019‑10 | 2018‑10 | 2017‑10 | 2016‑10 | 2015‑10 | |
| Income | |||||||||
Revenues | 868 -33.22% | 1,300 32.49% | |||||||
Cost of revenue | 1,097 | 1,322 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (230) | (22) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 11 | ||||||||
Tax Rate | |||||||||
NOPAT | (230) | (33) | |||||||
Net income | (547) 240.38% | (161) -73.73% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 23 | 28 | |||||||
Long-term debt | 35 | ||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 5 | 22 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (17) | (4) | |||||||
CAPEX | (2) | (3) | |||||||
Cash from investing activities | (3) | ||||||||
Cash from financing activities | (5) | 26 | |||||||
FCF | 319 | 39 | |||||||
| Balance | |||||||||
Cash | 18 | 40 | |||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | (841) | (294) | |||||||
Invested Capital | 23 | 62 | |||||||
ROIC | |||||||||
ROCE | 28.07% | 9.70% | |||||||
| EV | |||||||||
Common stock shares outstanding | 68,886 | 68,886 | |||||||
Price | 1.25 -14.38% | ||||||||
Market cap | 86,107 -14.38% | ||||||||
EV | 86,130 | ||||||||
EBITDA | (122) | 84 | |||||||
EV/EBITDA | 1,021.02 | ||||||||
Interest | 28 | 11 | |||||||
Interest/NOPBT | |||||||||